Detail of "89371-37-9"

Reference

Combined effect of imidapril, a novel ACE inhibitor, with hydrochlorothiazide or diltiazem on blood pressure in SHRs (spontaneously hypertensive rats)

Combined effect of imidapril, a novel ACE inhibitor, with hydrochlorothiazide or diltiazem on blood pressure in SHRs (spontaneously hypertensive rats). Ogiku, Noriko; Nakao, Masaharu; Knbo, Masami; Ishida, Ryuichi (Pharmacol. Res. Lab., Tanabe Seiyaku Co., Ltd., Japan). Yakuri to Chiryo, 19(12), 4821-4 (Japanese) 1991. CODEN: YACHDS. 58-93-5 and 89371-37-9 are also in the experiment. ISSN: 0386-3603. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Imidapril (5 mg/kg) was administered to SHRs orally once a day for 15 days simultaneously with hydrochlorothiazide (10 mg/kg) or diltiazem (50 mg/kg). In combination with hydrochlorothiazide or diltiazem, the antihypertensive effect of imidapril was clearly augmented on the 15th day though it was less on the 8th day. Thus the antihypertensive effect of imidapril in SHRs is augmented by thiazide diuretics and Ca entry blockers. .

Effects of imidapril on left ventricular mass in chronic hemodialysis patients

All Rights Reserved. Effects of imidapril on left ventricular mass in chronic hemodialysis patients. Matsumoto, Nobuko; Ishimitsu, Toshihiko; Okamura, Atsushi; Seta, Hitoshi; Takahashi, Masaki; Matsuoka, Hiroaki (Department of Hypertension and Cardiorenal Medicine, Dokkyo Medical University, Tochigi, Japan). Hypertension Research, 29(4), 253-260 (English) 2006 Japanese Society of Hypertension. CODEN: HRESE4. ISSN: 0916-9636. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Left ventricular hypertrophy is considered to be a major cardiovascular risk factor in hemodialysis patients. 89371-37-9 is the cas registry number. This chemical is also mentioned in this article. Not only high blood pressure but also humoral factors such as angiotensin II and aldosterone are thought to contribute to the increase in left ventricular mass. We examd. the effects of an angiotensin converting enzyme (ACE) inhibitor, imidapril, on left ventricular mass in patients with end-stage renal diseases on maintenance hemodialysis. Thirty patients on chronic hemodialysis were randomly divided into 2 groups of 15 patients each and given placebo or 2.5 mg imidapril once daily for 6 mo. Before and after the 6-mo period, left ventricular mass was evaluated by echocardiog., and circulating factors of the renin-angiotensin-aldosterone system were measured. Background characteristics such as age, gender ratio, causes of renal failure, duration of hemodialysis, body mass index and pre-dialysis blood pressure were comparable between the placebo and the imidapril groups. Systolic and diastolic blood pressures were not significantly changed in either group during the study period. In the imidapril group, serum ACE was reduced (12±1 to 5±2 U/l, p<0.01) and plasma renin activity was increased (3.3±0.8 to 8.1±3.2 ng/mL/h, p<0.01), but plasma angiotensin II and aldosterone were not significantly changed after 6 mo (13±3 to 17±3 pg/mL and 365±125 to 312±132 pg/mL, resp.). On the other hand, left ventricular mass index was significantly decreased in the imidapril group (132±10 to 109±6 g/m2, p<0.05) but was unchanged in the placebo group (129±6 to 126±5 g/m2). These results suggest that an ACE inhibitor reduces left ventricular mass in hemodialysis patients by a mechanism that is independent of changes in blood pressure. .